Attitude towards remission induction for elderly patients with acute myeloid leukemia influences survival

被引:68
作者
Juliusson, G
Billström, R
Gruber, A
Hellström-Linderg, E
Höglund, M
Karlsson, K
Stockelberg, D
Wahlin, A
Åström, M
Arnesson, C
Brunell-Abrahamsson, U
Carstensen, J
Fredriksson, E
Holmberg, E
Nordenskjöld, K
Wiklund, F
机构
[1] Univ Hosp & Reg Oncol Ctr, Dept Hematol, Linkoping, Sweden
[2] Univ Hosp & Reg Oncol Ctr, Dept Hematol, Lund, Sweden
[3] Karolinska Univ Hosp, Dept Hematol, Stockholm, Sweden
[4] Reg Oncol Ctr, Stockholm, Sweden
[5] Karolinska Univ Hosp, Dept Hematol, Huddinge, Sweden
[6] Acad Hosp & Reg Oncol Ctr, Dept Med, Uppsala, Sweden
[7] Sahlgrens Univ Hosp, Dept Med, Gothenburg, Sweden
[8] Reg Oncol Ctr, Dept Med, Gothenburg, Sweden
[9] Norrland Univ Hosp, Dept Med, Umea, Sweden
[10] Reg Oncol Ctr, Umea, Sweden
[11] Univ Hosp, Dept Med, Orebro, Sweden
关键词
acute myeloid leukemia; elderly; remission induction; population based; palliation;
D O I
10.1038/sj.leu.2404004
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Combination chemotherapy may induce remission from acute myeloid leukemia (AML), but validated criteria for treatment of elderly are lacking. The remission intention ( RI) rate for elderly patients, as reported to the Swedish Leukemia Registry, was known to be different when comparing the six health care regions, but the consequences of different management are unknown. The Leukemia Registry, containing 1672 AML patients diagnosed between 1997 and 2001, with 98% coverage and a median follow-up of 4 years, was completed with data from the compulsory cancer and population registries. Among 506 treated and untreated patients aged 70-79 years with AML (non-APL), there was a direct correlation between the RI rate in each health region ( range 36-76%) and the two-year overall survival, with no censored observations (6-21%) ( v 2 for trend = 11.3, P < 0.001; r(2) = 0.86, P < 0.02, nonparametric). A 1-month landmark analysis showed significantly better survival in regions with higher RI rates ( P = 0.003). Differences could not be explained by demographics, and was found in both de novo and secondary leukemias. The 5-year survival of the overall population aged 70-79 years was similar between the regions. Survival of 70-79-year-old AML patients is better in regions where more elderly patients are judged eligible for remission induction.
引用
收藏
页码:42 / 47
页数:6
相关论文
共 27 条
[1]
Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study [J].
Anderson, JE ;
Kopecky, KJ ;
Willman, CL ;
Head, D ;
O'Donnell, MR ;
Luthardt, FW ;
Norwood, TH ;
Chen, IM ;
Balcerzak, SP ;
Johnson, DB ;
Appelbaum, FR .
BLOOD, 2002, 100 (12) :3869-3876
[2]
Adjustment of incidence rates after an estimate of completeness and accuracy in registration of acute leukemias in a Swedish population [J].
Åström, M ;
Bodin, L ;
Tidefelt, U .
LEUKEMIA & LYMPHOMA, 2001, 41 (5-6) :559-570
[3]
Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720 [J].
Baer, MR ;
George, SL ;
Dodge, RK ;
O'Loughlin, KL ;
Minderman, H ;
Caligiuri, MA ;
Anastasi, J ;
Powell, BL ;
Kolitz, JE ;
Schiffer, CA ;
Bloomfield, CD ;
Larson, RA .
BLOOD, 2002, 100 (04) :1224-1232
[4]
BILLSTROM R, 1998, 1 SWED NAT REG AC LE
[5]
BILLSTROM R, 2002, 3 SWED NAT REG AC LE
[6]
BILLSTROM R, 1999, 2 SWED NAT REG AC LE
[7]
Burnett AK, 2002, BLOOD, V100, p155A
[8]
Treatment of newly-diagnosed acute myelogenous leukaemia in patients aged 80 years and above [J].
DeLima, M ;
Ghaddar, H ;
Pierce, S ;
Estey, E .
BRITISH JOURNAL OF HAEMATOLOGY, 1996, 93 (01) :89-95
[9]
Acute myeloid leukemia in elderly patients aged over 75 years:: Experience of a single centre [J].
Di Febo, A ;
Mele, L ;
Fianchi, L ;
Scardocci, A ;
Voso, MT ;
Falcucci, P ;
Trapè, G ;
Leone, G ;
Pagano, L .
LEUKEMIA & LYMPHOMA, 2003, 44 (08) :1441-1443
[10]
How I treat older patients with AML [J].
Estey, EH .
BLOOD, 2000, 96 (05) :1670-1673